BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program. The biotechnology startup, which is headquartered in San Francisco, California, USA, was selected for the development of its universal adeno-associated virus (AAV) immuno-gene therapy for cancer..

马萨诸塞州伯灵顿市。-（商业新闻短讯）--德国达姆施塔特默克公司（Merck KGaA）美国和加拿大生命科学公司MilliporeSigma今天宣布，Siren Biotechnology已被选为其第13个高级生物技术资助计划的北美获胜者。这家总部位于美国加利福尼亚州旧金山的生物技术初创公司被选中开发其针对癌症的通用腺相关病毒（AAV）免疫基因疗法。。

'Emerging biotech companies play a critical role in driving innovation and development in life sciences, owning 60 percent of the current drug pipeline1,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. “Our Advance Biotech Grant Program provides the products, technologies and services to help these companies bring their life-changing innovations to market, and ultimately, patients around the world.”.

德国达姆施塔特默克公司生命科学业务流程解决方案负责人塞巴斯蒂安·阿拉纳（SebastianArana）表示：“新兴生物技术公司在推动生命科学创新和发展方面发挥着关键作用，拥有目前药物管道的60%。”。“我们的高级生物技术资助计划提供产品、技术和服务，帮助这些公司将其改变生活的创新推向市场，并最终将其推向世界各地的患者。”。

Millions of people worldwide are affected by cancer. To meet the demand for cancer-treating therapies, Siren Biotechnology is developing a universal AAV immuno-gene therapy platform designed to reduce development and manufacturing timelines, while also working for numerous types of cancer.

全世界数百万人受到癌症的影响。为了满足癌症治疗的需求，Siren Biotechnology正在开发一种通用的AAV免疫基因治疗平台，旨在缩短开发和制造时间表，同时也为多种类型的癌症工作。

As part of the award, Siren Biotechnology will receive a wide range of support from MilliporeSigma, including Millipore® bioprocessing products, technologies and consultative services, and close partnership with the company to screen different media formulations to help optimize AAV yield. Siren Biotechnology will leverage the company's BioReliance® Contract Testing Services for AAV testing, as well as consultation services and training by technical experts from the Emprove® team and M Lab™ Collaboration Center.

作为该奖项的一部分，Siren Biotechnology将获得MilliporeSigma的广泛支持，包括Millipore®生物加工产品、技术和咨询服务，并与该公司密切合作，筛选不同的培养基配方，以帮助优化AAV产量。Siren Biotechnology将利用公司的BioReliance®合同测试服务进行AAV测试，以及来自Emprove®团队和M Lab™协作中心的技术专家的咨询服务和培训。

Managed by an experienced team of engineers and scientists, MilliporeSigma’s M Lab™ Collaboration Centers allow customers to explore technical solutions, test applications, assess technologies, and optimize processes. Additionally, MilliporeSigma’s Emprove® Program combines high-quality products, comprehensive documentation, and customer support to facilitate qualification, risk assessment, and process optimization..

MilliporeSigma的M Lab™协作中心由经验丰富的工程师和科学家团队管理，允许客户探索技术解决方案、测试应用程序、评估技术和优化流程。此外，MilliporeSigma的Emprove®计划结合了高质量的产品、全面的文档和客户支持，以促进资格认证、风险评估和流程优化。。

Since 2014, the Life Science business’s Advance Biotech Grant Program has awarded technologies and consultation to more than 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders.

自2014年以来，生命科学商业的高级生物技术资助计划已向全球40多家生物技术公司授予技术和咨询服务，支持他们努力改善癌症，脑瘤，骨关节炎和心血管疾病等各种疾病的患者预后。

The company is set to award additional grants in APAC in July and EMEA in November, further expanding its commitment to supporting emerging biotech companies worldwide..

该公司将于7月在亚太地区和11月在欧洲、中东和非洲地区发放额外赠款，进一步扩大其支持全球新兴生物技术公司的承诺。。

About the Life Science business of Merck KGaA, Darmstadt, Germany

关于德国达姆施塔特默克公司的生命科学业务

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.

德国达姆施塔特默克公司（Merck KGaA）的生命科学业务在美国和加拿大作为MilliporeSigma运营，在全球拥有28000多名员工和55多个总制造和测试站点，拥有300000多种产品，专注于科学发现、生物制造和测试服务。

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics..

德国达姆施塔特默克公司是一家领先的科技公司，经营医疗保健、生命科学和电子产品。。

Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere.

大约63000名员工通过创造更快乐和可持续的生活方式，每天努力为数百万人的生活带来积极的影响。从提供加速药物开发和制造的产品和服务，以及发现治疗最具挑战性疾病的独特方法，到实现设备的智能化，该公司无处不在。

In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries..

2023年，德国达姆施塔特默克公司在65个国家的销售额达到210亿欧元。。

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics.

该公司在国际上拥有“默克”名称和商标的全球权利。唯一的例外是美国和加拿大，德国达姆施塔特默克公司（Merck KGaA）的业务部门在生命科学领域担任MilliporeSigma，在医疗保健领域担任EMD Serono，在电子领域担任EMD Electronics。

Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com..

自1668年成立以来，科学探索和负责任的创业精神一直是该公司技术和科学进步的关键。直到今天，创始家族仍然是这家上市公司的主要所有者。有关德国达姆施塔特默克公司的更多信息，请访问www.emdgroup.com。。

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

关注Twitter@MilliporeSigma、Facebook@MilliporeSigma和LinkedIn上的MilliporeSigma。

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email.

所有默克公司（Merck KGaA）、达姆施塔特（Darmstadt）的新闻稿均通过电子邮件分发，同时可在EMD集团网站上查阅。如果您是美国或加拿大居民，请访问www.emdgroup.com/subscribe再次注册您在线订阅此服务，因为我们新推出的地理定位需要电子邮件中的新链接。

You may later change your selection or discontinue this service..

您可以稍后更改选择或停止此服务。。

______________________________

______________________________

1 1Q24 Molecule Pipeline from Evaluate Pharma, Global Data and CNDA

1来自Evaluate Pharma、Global Data和CNDA的1Q24分子管道